A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

Joan E. Smallshaw; Ellen S. Vitetta

doi:10.1016/j.vaccine.2009.12.081

A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

Joan E. Smallshaw, Ellen S. Vitetta

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.

Original language	English (US)
Pages (from-to)	2428-2435
Number of pages	8
Journal	Vaccine
Volume	28
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2009.12.081
State	Published - Mar 11 2010

Keywords

Lyophilization
Ricin
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2009.12.081

Cite this

@article{0c2542b765bc4b79a96d3da8d90efa09,

title = "A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity",

abstract = "Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.",

keywords = "Lyophilization, Ricin, Vaccine",

author = "Smallshaw, {Joan E.} and Vitetta, {Ellen S.}",

note = "Funding Information: Supported by NIH grant AI-056372 .",

year = "2010",

month = mar,

day = "11",

doi = "10.1016/j.vaccine.2009.12.081",

language = "English (US)",

volume = "28",

pages = "2428--2435",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

AU - Smallshaw, Joan E.

AU - Vitetta, Ellen S.

N1 - Funding Information: Supported by NIH grant AI-056372 .

PY - 2010/3/11

Y1 - 2010/3/11

N2 - Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.

AB - Ricin is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax) contains two mutations, rendering it non-toxic at high doses. Frozen or alum formulations of RiVax protected mice against ricin administered by injection, gavage or aerosol. Without alum, RiVax was safe and immunogenic in rabbits and human volunteers. For military use, the predominant target group, it would be optimal not to require a cold chain for transport and storage. We have now developed a lyophilized formulation and demonstrated stability and efficacy for at least 1 year stored refrigerated or at room temperature administered with or without alum.

KW - Lyophilization

KW - Ricin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77249085103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249085103&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.12.081

DO - 10.1016/j.vaccine.2009.12.081

M3 - Article

C2 - 20074685

AN - SCOPUS:77249085103

SN - 0264-410X

VL - 28

SP - 2428

EP - 2435

JO - Vaccine

JF - Vaccine

IS - 12

ER -

A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this